Artificial Intelligence: How Vendors Are Using It – November 2024
LSTLF Meeting: November 2024
The Life Sciences Technology Leadership Forum (LSTLF) convened on November 14, 2024 to discuss the integration and use of Artificial Intelligence (AI) in the life sciences industry, specifically focusing on how major vendors are incorporating generative AI technologies. Participants, including key IT and business leaders from various life sciences organizations, shared insights into their current AI strategies.
Over the course of the last several LSTLF discussions the conversation has shifted from theoretical explorations of AI to more actionable application of the technology. The latest discussion intended to spotlight generative AI technology and evaluate the value of offerings from prominent software platform providers like Veeva, SAP, Oracle, and Salesforce, aiming to discern whether such offerings are marketing-driven or genuinely transformative.
A portion of the discussion centered around the technology vendors, particularly Veeva, and the implementation, or lack thereof, of AI solutions in their platform. Participants frequented discussions about Veeva’s offerings, revealing that AI was not prominently featured in their existing documentation or initial sales pitches. Some attendees recounted direct interactions with Veeva representatives who explained that while the company would not develop in-house AI solutions, it plans to integrate AI services from third-party partners. This cautious approach reflects a broader trend among vendors who attempt to balance adoption of emerging technologies like AI with associated risks and ongoing platform transitions.
Conversations revealed that larger pharmaceutical corporations are actively investing in AI-driven efficiencies. For example, some Big Pharma companies are using AI to enhance productivity and speed up processes like regulatory submissions and clinical trial documentation generation. These advancements aim to drive significant organizational changes, such as accelerated drug development timelines and improved employee productivity.
Conversely, smaller biotech firms face limitations in AI technology adoption, primarily due to financial constraints and resource availability, leading them to focus on incremental productivity improvements rather than transformative change. Concerns were voiced about the potential competitive disadvantage for smaller firms as large pharmaceutical companies advance their AI capabilities.
A key observation among attendees was the lack of pressing demand for AI investments from their boards or senior management. While some companies experienced initial inquiries from executives about AI initiatives, the discussions rarely translated into substantial funding or strategic pressure.
The group acknowledged the importance of AI literacy across their organizations, emphasizing the need for internal education to prepare for potential future integration. Attendees shared that AI adoption is predominantly seen in enhancing individual productivity through existing tools like Microsoft’s Copilot, which offers immediate, albeit smaller-scale, efficiency gains. Indeed, several of the participating companies had “Copilot pilots” underway with representative participants from across the organization.
The forum concluded with reflections on navigating the AI landscape, especially the balance between innovation and practicality. Participants appreciated the opportunity to share insights and strategize collaboratively, recognizing that AI adoption requires thoughtful experimentation and a readiness to adapt to emerging possibilities. The session underscored the nuanced approach necessary for implementing AI solutions, with considerations ranging from employee skill development to larger strategic investments. This ongoing dialogue aims to foster a collaborative environment in which life sciences companies can collectively address the challenges and opportunities AI presents.
The LSTLF forum serves as a platform for discussion among leaders and professionals in the field, facilitating conversations around the integration and application of technologies in life sciences. The event is organized to create a space for sharing insights and validating approaches, emphasizing the role of AI in improving processes and outcomes.